Trial reportCardiovascular drugs and therapy2009
Selective PKC beta inhibition with ruboxistaurin and endothelial function in type-2 diabetes mellitus.
Trial report in Cardiovascular drugs and therapy, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 70 citations in OpenAlex.
- Inhibition of protein kinase Cbeta does not improve endothelial function in type 2 diabetes.The Journal of clinical endocrinology and metabolism · 2010Trial
- Protein kinase C and endothelial dysfunction in select vascular diseases.Frontiers in cardiovascular medicine · 2025Review
- Riluzole, a neuroprotective agent, preserves erectile function following bilateral cavernous nerve injury in male rats.International journal of impotence research · 2024Article
- PKC Inhibition Improves Human Penile Vascular Function and the NO/cGMP Pathway in Diabetic Erectile Dysfunction: The Role of NADPH Oxidase.International journal of molecular sciences · 2024Article
- PKCδ regulates the vascular biology in diabetic atherosclerosis.Cell communication and signaling : CCS · 2023Review
- Determination of Ruboxistaurin analysis in rat plasma utilizing LC-MS/MS technique.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2023Article
- The New Biology of Diabetic Kidney Disease-Mechanisms and Therapeutic Implications.Endocrine reviews · 2020Review
- A Protective Role of Paeoniflorin in Fluctuant Hyperglycemia-Induced Vascular Endothelial Injuries through Antioxidative and Anti-Inflammatory Effects and Reduction of PKCOxidative medicine and cellular longevity · 2019Article
- Evolving mechanisms of vascular smooth muscle contraction highlight key targets in vascular disease.Biochemical pharmacology · 2018Review
- Genetic Reduction in Left Ventricular Protein Kinase C-α and Adverse Ventricular Remodeling in Human Subjects.Circulation. Genomic and precision medicine · 2018Article
- Microvascular insulin resistance in skeletal muscle and brain occurs early in the development of juvenile obesity in pigs.American journal of physiology. Regulatory, integrative and comparative physiology · 2018Article
- Protein Kinase C as Regulator of Vascular Smooth Muscle Function and Potential Target in Vascular Disorders.Advances in pharmacology (San Diego, Calif.) · 2017Review
- Nanomedicines for Endothelial Disorders.Nano today · 2015Article
- Diabetes and cardiovascular disease: let's push forward with translational research.Cardiovascular diagnosis and therapy · 2015Article
- Docetaxel Facilitates Endothelial Dysfunction through Oxidative Stress via Modulation of Protein Kinase C Beta: The Protective Effects of Sotrastaurin.Toxicological sciences : an official journal of the Society of Toxicology · 2015Article
- Perivascular adipose tissue and coronary vascular disease.Arteriosclerosis, thrombosis, and vascular biology · 2014Review
- Indole diterpenoids and isocoumarin from the fungus, Aspergillus flavus, isolated from the prawn, Penaeus vannamei.Marine drugs · 2014Article
- Go-6976 reverses hyperglycemia-induced insulin resistance independently of cPKC inhibition in adipocytes.PloS one · 2014Article
- Protein kinase C-β contributes to impaired endothelial insulin signaling in humans with diabetes mellitus.Circulation · 2013 · on this mapArticle
- Epicardial perivascular adipose tissue as a therapeutic target in obesity-related coronary artery disease.British journal of pharmacology · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
Abstract
purposeType-2 diabetes mellitus increases risk of atherosclerotic cardiovascular disease. However, the mechanisms linking hyperglycemia and atherosclerosis remain poorly understood. One proposed mechanism involves endothelial dysfunction via activation of protein kinase C beta (PKC beta). Prior studies demonstrate beneficial effects of PKC beta inhibition on microvascular parameters, but, to date, no study has examined the effect on macrovascular atherosclerotic readouts.
methodsThe goal of this double-masked, placebo-controlled trial in type-2 diabetes was to assess the effect of the PKC beta-specific inhibitor, ruboxistaurin (32 mg/day for 6 weeks) on ultrasound assessed brachial artery flow mediated dilatation (FMD), a surrogate of macro vascular endothelial function, and urinary isoprostanes, indices of oxidant stress.
resultsCompared to placebo, ruboxistaurin tended to improve FMD (difference in 6-week change in FMD, mean +/- SD millimeter) at one (0.13 +/- 0.26 mm, p = 0.08) and 5 min (0.12 +/- 0.21 mm, p = 0.02) after cuff deflation, but had no effect on nitroglycerin-mediated dilatation or urinary isoprostanes.
conclusionsThis proof of concept trial is the first to suggest that specific inhibition of PKC beta may improve macro vascular endothelial function in type-2 diabetes. Larger trials including clinical endpoints are warranted to determine the potential efficacy of PKC beta inhibition in reducing atherosclerotic cardiovascular complications in diabetes mellitus.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.